The objectives of this prospective study were to evaluate the efficiency, safety and applicability of medium power (MP) holmium laser devices in the endoscopic enucleation of the enlarged prostate (HoLEP) compared to high power (HP) laser devices.
From October 2019 to July 2020, a total of 120 consecutive patients planned for HoLEP were divided randomly into two groups formed in terms of the power of the device used. While patients in Group 1 were treated with a MP device (50W) at 39.6-W (2.2J / 18Hz), patients in Group 2 were treated with HP (100W) device at 42W (1.2J / 35Hz). Pre-operative patient characteristics, peri- operative measures and 3-month functional outcomes were evaluated in both groups with an emphasis on enucleation efficiency (EE) and hemoglobin decrease in a comparative manner.
All patients underwent successful HoLEP surgery with no severe peri and post-op complications. No statistically significant differences were observed in terms of pre-op patient characteristics and peri-op measures in the two groups. The median EE values in Group 1 and Group 2 were 1.15 (IQR: 0.33-2.2) and 1.11 (IQR: 0.4-2.8), respectively (p = 0.775). Hemoglobin decrease values in Group 1 and Group 2 were 1.3 (IQR: 0.1-4) and 1.4 (IQR: 0.4-3.1), respectively (p = 0.736). There was no difference in terms of either catheterization time or hospital stay in the groups. In the model created to predict hemoglobin decrease, only biopsy was detected to be the independent predictive factor among the data from laser device, biopsy and antithrombotics use. Functional outcomes markedly improved in all patients without any statistically significant difference between the groups in the 3-month follow-up.
Our comparative study indicated that HoLEP can be performed safely and effectively with MP laser devices without any technical difficulties and with comparable results achieved in HP laser devices.

This article is protected by copyright. All rights reserved.